|
1
|
Shanahan CM, Crouthamel MH, Kapustin A and
Giachelli CM: Arterial calcification in chronic kidney disease: Key
roles for calcium and phosphate. Circ Res. 109:697–711. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Schlieper G, Schurgers L, Brandenburg V,
Reutelingsperger C and Floege J: Vascular calcification in chronic
kidney disease: An update. Nephrol Dial Transplant. 31:31–39. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Six I, Maizel J, Barreto FC, Rangrez AY,
Dupont S, Slama M, Tribouilloy C, Choukroun G, Mazière JC,
Bode-Boeger S, et al: Effects of phosphate on vascular function
under normal conditions and influence of the uraemic state.
Cardiovasc Res. 96:130–139. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Persy V and D'Haese P: Vascular
calcification and bone disease: The calcification paradox. Trends
Mol Med. 15:405–416. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Steitz SA, Speer MY, Curinga G, Yang HY,
Haynes P, Aebersold R, Schinke T, Karsenty G and Giachelli CM:
Smooth muscle cell phenotypic transition associated with
calcification: Upregulation of Cbfa1 and downregulation of smooth
muscle lineage markers. Circ Res. 89:1147–1154. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Giachelli CM: The emerging role of
phosphate in vascular calcification. Kidney Int. 75:890–897. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lanzer P, Boehm M, Sorribas V, Thiriet M,
Janzen J, Zeller T, St Hilaire C and Shanahan C: Medial vascular
calcification revisited: Review and perspectives. Eur Heart J.
35:1515–1525. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Brandenburg VM, Sinha S, Specht P and
Ketteler M: Calcific uraemic arteriolopathy: A rare disease with a
potentially high impact on chronic kidney disease-mineral and bone
disorder. Pediatr Nephrol. 29:2289–2298. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ivanova EA, Parolari A, Myasoedova V,
Melnichenko AA, Bobryshev YV and Orekhov AN: Peroxisome
proliferator-activated receptor (PPAR) gamma in cardiovascular
disorders and cardiovascular surgery. J Cardiol. 66:271–278. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wan Y: PPARγ in bone homeostasis. Trends
Endocrinol Metab. 21:722–728. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Li F, Cai Z, Chen F, Shi X, Zhang Q, Chen
S, Shi J, Wang DW and Dong N: Pioglitazone attenuates progression
of aortic valve calcification via down-regulating receptor for
advanced glycation end products. Basic Res Cardiol. 107:3062012.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Morena M, Jaussent I, Dupuy AM, Bargnoux
AS, Kuster N, Chenine L, Leray-Moragues H, Klouche K, Vernhet H,
Canaud B and Cristol JP: Osteoprotegerin and sclerostin in chronic
kidney disease prior to dialysis: Potential partners in vascular
calcifications. Nephrol Dial Transplant. 30:1345–1356. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Paloian NJ and Giachelli CM: A current
understanding of vascular calcification in CKD. Am J Physiol Renal
Physiol. 307:F891–F900. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yao L, Sun YT, Sun W, Xu TH, Ren C, Fan X,
Sun L, Liu LL, Feng JM, Ma JF and Wang LN: High phosphorus level
leads to aortic calcification via β-catenin in chronic kidney
disease. Am J Nephrol. 41:28–36. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Speer MY, Yang HY, Brabb T, Leaf E, Look
A, Lin WL, Frutkin A, Dichek D and Giachelli CM: Smooth muscle
cells give rise to osteochondrogenic precursors and chondrocytes in
calcifying arteries. Circ Res. 104:733–741. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
EI'chaninov DV, Akker LV, Fedorova IA and
Popovtseva AV: Bone resorption and formation markers in women with
climacteric syndrome in early postmenopause. Klin Lab Diagn. 21–24.
2009.(In Russian).
|
|
17
|
Woldt E, Terrand J, Mlih M, Matz RL,
Bruban V, Coudane F, Foppolo S, El Asmar Z, Chollet ME, Ninio E, et
al: The nuclear hormone receptor PPARγ counteracts vascular
calcification by inhibiting Wnt5a signalling in vascular smooth
muscle cells. Nat Commun. 3:10772012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhou YB, Zhang J, Peng DQ, Chang JR, Cai
Y, Yu YR, Jia MZ, Wu W, Guan YF, Tang CS and Qi YF: Peroxisome
proliferator-activated receptor γ ligands retard cultured vascular
smooth muscle cells calcification induced by high glucose. Cell
Biochem Biophys. 66:421–429. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Boyden LM, Mao J, Belsky J, Mitzner L,
Farhi A, Mitnick MA, Wu D, Insogna K and Lifton RP: High bone
density due to a mutation in LDL-receptor-related protein 5. N Engl
J Med. 346:1513–1521. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Balemans W, Patel N, Ebeling M, Van Hul E,
Wuyts W, Lacza C, Dioszegi M, Dikkers FG, Hildering P, Willems PJ,
et al: Identification of a 52 kb deletion down-stream of the SOST
gene in patients with van Buchem disease. J Med Genet. 39:91–97.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Bodine PV, Zhao W, Kharode YP, Bex FJ,
Lambert AJ, Goad MB, Gaur T, Stein GS, Lian JB and Komm BS: The Wnt
antagonist secreted frizzled-related protein-1 is a negative
regulator of trabecular bone formation in adult mice. Mol
Endocrinol. 18:1222–1237. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Glass DA II, Bialek P, Ahn JD, Starbuck M,
Patel MS, Clevers H, Taketo MM, Long F, McMahon AP, Lang RA and
Karsenty G: Canonical Wnt signaling in differentiated osteoblasts
controls osteoclast differentiation. Dev Cell. 8:751–764. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Holmen SL, Zylstra CR, Mukherjee A, Sigler
RE, Faugere MC, Bouxsein ML, Deng L, Clemens TL and Williams BO:
Essential role of beta-catenin in postnatal bone acquisition. J
Biol Chem. 280:21162–21168. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Morvan F, Boulukos K, Clément-Lacroix P,
Roman S Roman, Suc-Royer I, Vayssière B, Ammann P, Martin P, Pinho
S, Pognonec P, et al: Deletion of a single allele of the Dkk1 gene
leads to an increase in bone formation and bone mass. J Bone Miner
Res. 21:934–945. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Li J, Sarosi I, Cattley RC, Pretorius J,
Asuncion F, Grisanti M, Morony S, Adamu S, Geng Z, Qiu W, et al:
Dkk1-mediated inhibition of Wnt signaling in bone results in
osteopenia. Bone. 39:754–766. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Nakanishi T, Yamaai T, Asano M, Nawachi K,
Suzuki M, Suqimoto T and Takiqawa M: Overexpression of connective
tissue growth factor/hypertrophic chondrocyte-specific gene product
24 decreases bone density in adult mice and induces dwarfism.
Biochem Biophys Res Commun. 281:678–681. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
MacDonald BT, Tamai K and He X:
Wnt/beta-catenin signaling: Components, mechanisms, and diseases.
Dev Cell. 17:9–26. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Jansson EA, Are A, Greicius G, Kuo IC,
Kelly D, Arulampalam V and Pettersson S: The Wnt/beta-catenin
signaling pathway targets PPARgamma activity in colon cancer cells.
Proc Natl Acad Sci USA. 102:1460–1465. 2005; View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Guo F, Ren X, Dong Y, Hu X, Xu D, Zhou H,
Meng F, Tian W and Zhao Y: Constitutive expression of PPARγ
inhibits proliferation and migration of gastric cancer cells and
down-regulates Wnt/β-catenin signaling pathway downstream target
genes TERT and ENAH. Gene. 584:31–37. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Liu J, Wang H, Zuo Y and Farmer SR:
Functional interaction between peroxisome proliferator-activated
receptor gamma and beta-catenin. Mol Cell Biol. 26:5827–5837. 2006.
View Article : Google Scholar : PubMed/NCBI
|
